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Abstract
Background: Clinical trials typically have a relatively short follow-up period, and may both underestimate potential
benefits of treatments investigated, and fail to detect hazards, which can take much longer to emerge. Prolonged
follow-up of trial participants after the end of the scheduled trial period can provide important information on both
efficacy and safety outcomes. This protocol describes a systematic review to qualitatively compare methods of
post-trial follow-up used in large randomized controlled trials.
Methods/design: A systematic search of electronic databases and clinical trial registries will use a predefined
search strategy. All large (more than 1000 adult participants) randomized controlled trials will be evaluated. Two
reviewers will screen and extract data according to this protocol with the aim of 95% concordance of papers
checked and discrepancies will be resolved by a third reviewer. Trial methods, participant retention rates and
prevalence of missing data will be recorded and compared. The potential for bias will be evaluated using the
Cochrane Risk of Bias tool (applied to the methods used during the in-trial period) with the aim of investigating
whether the quality of the post-trial follow-up methodology might be predicted by the quality of the methods
used for the original trial.
Discussion: Post-trial follow-up can provide valuable information about the long-term benefits and hazards of
medical interventions. However, it can be logistically challenging and costly. The aim of this systematic review is
to describe how trial participants have been followed-up post-trial in order to inform future post-trial follow-up
designs.
Systematic review registration: Not applicable for PROSPERO registration.
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Background
Randomized controlled trials (RCTs) are considered to
be the gold standard for assessing the effects of a treat-
ment. However, RCTs are costly and usually involve a
relatively brief treatment period with limited follow-up.
A treatment response restricted to this brief “in-trial”
period can potentially underestimate the long-term ben-
efits of treatment and also may fail to detect delayed
hazards.
Post-trial follow-up (PTFU) is defined here as ex-
tended follow-up which starts after the end of the
scheduled period of the original trial. Longer term
follow-up of trial participants is important as persistent
effects may be detected years later after treatment ces-
sation [1] or even enhanced benefits observed decades
later—a so-called “legacy-effect” [2]. Furthermore,
delayed hazards may only emerge several years after ex-
posure to certain treatments. Therefore, PTFU may add
significant scientific value to the evaluation of many
healthcare interventions.
There is a wide literature describing the importance
of completeness of follow-up during the in-trial period
of a RCT, without which the unbiased ascertainment of
outcomes may be compromised and statistical power
considerably reduced [3]. Many strategies to enhance
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follow-up during RCTs have been investigated and this
remains an area of much ongoing research [4]. Without
high quality in-trial follow-up, the value of post-trial
follow-up will be extremely limited.
By contrast, little research has been done to evaluate
methods for PTFU. Face-to-face follow-up is widely used
during the initial "in-trial" period, but is costly if
employed longer term. Telephone-based approaches are
more practical, with the ability to contact many partici-
pants coordinated by a central trial office, and postal
follow-up has been shown to be effective [1]. Web-based
techniques may become more widespread as techno-
logical advances develop [5].
The use of routine health records can provide detailed
information relatively inexpensively [6], but the availabil-
ity of such data and rules governing access to it varies
across countries. In the UK, Health Episode Statistics
(HES) are held by the Health and Social Care Informa-
tion Centre (HSCIC) and can be used as a streamlined
method to follow-up trial participants. These routinely
collected electronic health records include diagnostic
codes (ICD-10) for hospital admissions and can be sup-





All published, health-related RCTs which have recruited
more than 1000 participants and implemented PTFU are
to be included in this systematic review. The RCT must
have reached its scheduled end before PTFU com-
menced. Only studies published between 2006 and 2016
will be included.
Health-related interventions will include medical (li-
censed or unlicensed drugs), surgical, or psychological
treatments. There will be no time limit of post-trial
follow-up (Table 1).
Participants
Trials including participants aged over 18 years old are
eligible.
Interventions
Methods and incentives (monetary or by other means)
used for post-trial follow-up including direct “face-to-
face” follow-up and indirect follow-up, eg, medical
record review, telephone and postal follow-up, and elec-
tronic follow-up including access to electronic health
records will be included.
Comparators
Methodology used to follow up participants’ post trial
will be compared qualitatively in a table format.
Outcome measures
Included studies must have published the total number
of participants followed-up compared to the total num-
ber alive at the end of the in-trial period to calculate re-
tention rates. Where available, secondary outcome
measures of cost, incentives used for follow-up, and
cost-effectiveness will be recorded and assessed. If there
are missing data, an attempt to contact the study au-
thors will be made. Further exploratory comparisons
will be made depending on the information available
(for example, describing the use of different approaches
according to context, such as regional variations or
comparisons of industry-funded trials versus those
funded through other sources).
Language
Only studies published in English will be included.
Search methods
Electronic searches
The electronic search strategy includes the last 10 years of
published articles using broad search criteria (Appendix).
Searches for eligible studies will take place in a struc-
tured, step-wise process. A screening log will be kept.
Results of searches from each electronic database and
registries will be logged. The following electronic data-
bases will be searched:
Table 1 Selection criteria of published articles eligible for
systematic review
Criteria Variables
Inclusion criteria • Large (>1000 participants) randomized
controlled trials only
• Randomized controlled trials in adult humans
• Any type of methodology used for post-trial
follow-up
• Healthcare intervention for the purpose
of treatment
• Published articles







• Books and book chapters
• Conference proceedings
• Lectures and addresses
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 Cochrane methodology group register




Other sources of searches will include the following
trials registry:
 Trials registry: Clinical-trials.gov
(http://clinicaltrials.gov/)
Screening for eligible studies
One reviewer will compile the titles and abstracts of all
citations retrieved from the electronic database searches
and order these by record number in Endnote® reference
management software. Duplicates will be removed using
the “deduplication tool” [7]. The screening process will
involve two reviewers. The first 10% of abstracts will be
screened by both reviewers independently. Concordance
of 95% between both reviewers’ decisions on screening
will be sought. If concordance is not reached at this
point, discrepancies will be discussed and reviewed
Fig. 1 Process of screening abstracts and checking for concordance between reviewers
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(including consultation with a third reviewer if neces-
sary), and a further 10% of abstracts will be reviewed
(Fig. 1). Once concordance has been reached, the
remaining records for screening will be shared equally
between the two reviewers and abstracts will be
checked for eligibility. All records that are considered
to be eligible will be confirmed by both reviewers. Full-
text papers will be requested for all potential eligible
papers.
Data collection and analysis
Data extraction and management
Two reviewers will follow a similar step-wise process
for data extraction (Fig. 2). A data extraction form will
be used, and data extracted from all eligible studies will
be compared qualitatively. All data regarding the inter-
vention, the participants (demographics), attrition, re-
tention, incentives used, and if specified, costs of PTFU
will be extracted. If required data items are not
available in the published article, the study’s corre-
sponding authors will be contacted. If no response is
received after two further attempts or from an alterna-
tive contact, the study will be excluded from the ana-
lysis but recorded on the PRISMA diagram and in an
appendix.
Assessing the quality of the post-trial follow-up
methodology
In order to investigate whether the quality of the post-
trial follow-up methodology might be predicted by the
quality of the methods used for the original trial, risk of
bias will be assessed in those trials chosen for data ex-
traction using the Cochrane Risk of Bias tool. The tool
will be applied to the methods used in the main trial,
(not the PTFU) focusing on incomplete data; outcome
reporting; for-profit bias and other bias sources. Two re-
viewers will independently assess the risk of bias, and dis-
agreements will be resolved by a third reviewer. The
Fig. 2 Process of extracting data and checking for concordance between reviewers
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assessment of bias results will be taken into account as part
of the assessment of quality of the PTFU methods used.
Presenting and reporting of results
The Preferred Reporting Items for Systematic Review
Protocols (PRISMA-P) [8] will be followed, including a
PRISMA diagram to illustrate the process of selecting
eligible studies (Fig. 1). Using the PRISMA guidelines
(Additional file 1), the results of this review will be presented
and the outcomes tabulated with respect to the different
methodologies used in a qualitative and comparative style.
Interpretation of findings
The findings of this review will be discussed and poten-
tial limitations considered.
Discussion
Large randomized trials are essential for determining the
magnitude of the effects of an intervention. Post-trial
follow-up of large RCTs is important, not only for defin-
ing the effect of an intervention long-term but also for
ascertaining the safety profile and potential hazards
which might not be apparent during the relatively brief
in-trial period. However, randomized trials can be very
expensive, and funding is limited, hence streamlined and
effective methodology for PTFU is desirable. This sys-
tematic review aims to inform the design of post-trial




 Search conducted via OvidSP interface: 1946 to
present in process and other non-indexed citations
Key to operators used in MEDLINE/Ovid: where.pt is
publication type, (?) represents any single character, (*)
is a group of characters,.mp.is multi-purpose search,/is
Medical Subject Headings (MeSH), exp is explode sub-
ject heading,.sh. is subject heading, (“ “) is phrase search.
EMBASE search strategy
 Search conducted via OvidSP interface 1974–2016,
March 04
Step Search domain Search terms
1 Randomized controlled trials randomized controlled trial.pt. or random?ed control* trial*.mp. or random allocation/
2 Post- trial (Post-trial or post trial or attrition or drop out? or dropout? or follow-up or followup? or extension* or trial closure?
or long-term or longterm or extended observation* or extended stud*).mp.
3 Outcomes (cost effective* or cost benefit* or costs or survivors or hospital admission? or hospitali?ation? or primary
outcome* or secondary outcome* or primary endpoint? or secondary endpoint? or composite endpoint? or
primary end point? or secondary end point? or composite end point? or outcome measure* or outcome
assessment or outcomes research).mp. or treatment outcome/
4 Types of methodological
follow-up
electronic data processings/or automatic data processing/or “surveys and questionnaires”/or telephone/or
interview/or data collection methods/or data collection/or data linkage/or data system?.mp. or data reporting/or
epidemiologic method?.mp. or incidence.mp. or mortality.mp. or health episode statistics.mp. or electronic health
record?.mp. or electronic patient record?.mp. or computeri?ed record-linkage system?.mp. or national register*.mp.
or national database*.mp. or episode of care/or routine data.mp. or routinely collected data.mp.
5 1 and 2 and 3 or 4
6 5 exp animals/not humans.sh.
7 6 limit to (abstracts and English language and yr=“2006 -Current”)
Step Search terms
1 exp medical record/or interview/or telephone interview/or
survey?.mp. or questionnaire?.mp. or data system?.mp. or
epidemiologic method?.mp. or incidence.tw. or mortality.tw. or
cardiovascular mortality/or cancer mortality/or *mortality/or health
episode statistics.mp. or electronic health record?.mp. or electronic
patient record?.mp. or computeri?ed record-linkage system?.mp. or
national registr*.mp. or national database*.mp. or routine data.mp.
or routinely collected data.mp.
2 (cost effective* or cost benefit* or costs).mp. or clinical
effectiveness/or effectiveness.mp. or survivors.mp. or hospital
admission?.mp. or hospital episode?.mp. or hospitali?ation?.mp.
or primary outcome*.mp. or secondary outcome*.mp. or outcome
measure*.mp. or outcome assessment.mp. or outcomes
research.mp. or treatment outcome/or treatment duration/
3 randomized controlled trial/or ((random* or blind* or placebo*).tw.
and major clinical study/)
4 (Post-trial or posttrial or attrition or drop out? or dropout? or
follow-up or followup? or extension* or trial closure? or long-term
or longterm or extended observation*).mp.
5 1 and 2 and 3 and 4
6 (exp animals/or nonhuman/) not human/
7 5 not 6
8 limit 7 to (english language and yr=“2000 -Current”)
9 (letter or editorial or conference*).pt.
10 8 not 9
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Cochrane Library search strategy
 Search conducted via Cochrane Library via Wiley
interface
 Cochrane Central Register for Controlled Trials
(Issue 2 of 12, February 2016)
 Cochrane Methods Register (Issue 3 of 4, July 2012)
Clinical Trials search strategy
 https://clinicaltrials.gov/
Comments:
All results will be downloaded with all fields dis-
played and in a tab delimited format. This file will then
be opened in ExCel. Duplicates will be removed. The
spreadsheet sort order will be changed to enrollment
A-Z and studies with fewer than 1000 enrolees will be
removed.
Additional file
Additional file 1: PRISMA-P (Preferred Reporting Items for Systematic
Review and Meta-Analysis Protocols) 2015 checklist: recommended items
to address in a systematic review protocol: recommended items to ad-
dress in a systematic review protocol. (DOC 85 kb)
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